RVL Pharmaceuticals plc
https://www.rvlpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From RVL Pharmaceuticals plc
Deal Watch: Roche, PhoreMost Enter Into Multi-Target Collaboration
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
Finance Watch: Three Newly Public Companies Face Mixed Reception In Early Trading
Also, two more health care-focused SPACs went public, Centessa obtained up to $300m in debt, three new venture capital funds launched and Intergalactic debuted with a $75m series A round.
Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Other Names / Subsidiaries
-
- Lilydale Limited
- RevitaLid, Inc.
- Osmotica Pharmaceutical Corp
- Osmotica Pharmaceuticals Limited
- Osmotica Pharmaceutical, Plc. RVL Pharmaceuticals Inc..
- Vertical Pharmaceuticals, Inc.
- Vertical / Trigen Holdings, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice